Holen Sie sich die Stockscreener-App
28.62
4.02%
-1.20
Handel nachbörslich:
29.06
0.44
+1.54%
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
Insider Sell: Louis Lange Sells 44,619 Shares of NewAmsterdam Ph - GuruFocus
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Capital World Investors - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Shares Bought by American Century Companies Inc. - MarketBeat
Louis Lange Sells 28,186 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells $3,165,350.10 in Stock - MarketBeat
Johannes Jacob Piete Kastelein Sells 101,409 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
(NAMS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Trend Report: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullishMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Stock Recap: Is NewAmsterdam Pharma Company NV Equity Warrant stock trending bullish2025 Technical Patterns & Smart Money Movement Tracker - baoquankhu1.vn
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - Defense World
NewAmsterdam Pharma Hits Day Low at $30.20 Amid Price Pressure - Markets Mojo
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews
NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView
NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseStill a Buy? - MarketBeat
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation - TipRanks
NewAmsterdam posts updated investor presentation highlighting obicetrapib efficacy, safety, IP and cash runway - TradingView
Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan
Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Sahm
JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NAMS) CEO exercises options and sells 306,293 shares - Stock Titan
Liquidity Mapping Around (NAMS) Price Events - Stock Traders Daily
Michael Davidson Sells 183,332 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
Rate Hike: Is NewAmsterdam Pharma Company NV stock overvalued or fairly pricedJuly 2025 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
NAMS Stock Price and Chart — NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Play with 34.71% Upside Potential - DirectorsTalk Interviews
Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock - MarketBeat
NewAmsterdam Pharma CSO Sells Shares - TradingView
NewAmsterdam Pharma (NAMS) CSO executes 45,481-share stock sale - Stock Titan
[144] NewAmsterdam Pharma Co N.V. SEC Filing - Stock Titan
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following Obicetrapib-Focused 2025 Results And Share Shelf Filing - simplywall.st
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
NAMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Q1 Earnings Forecast for NAMS Issued By HC Wainwright - MarketBeat
Published on: 2026-02-22 03:05:00 - baoquankhu1.vn
Can NewAmsterdam Pharma Company N.V. Equity Warrant stock beat analyst upgradesGap Up & Reliable Volume Spike Alerts - mfd.ru
What is HC Wainwright's Estimate for NAMS Q3 Earnings? - MarketBeat
6,000‑Share Rule 144 Sale by NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan
Cantor Fitzgerald Maintains Overweight on NAMS NewAmsterdam Pharma Feb 2026 - Meyka
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight - Investing.com Nigeria
Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing - Investing.com Nigeria
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight By Investing.com - Investing.com Australia
Readystate Asset Management LP Sells 196,841 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Ideas Watch: What are NewAmsterdam Pharma Company NVs technical support levels2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Aberdeen Group plc Has $18.83 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Needham & Company LLC Issues Positive Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World
Decoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT Insi - GuruFocus
Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co - Benzinga
Earnings Summary: NewAmsterdam Pharma Co Q4 - Benzinga
NewAmsterdam Pharma Narrows Net Loss in 2025, Revenue Drops - marketscreener.com
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times
NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: Potential 41% Upside Beckons Investors Despite Current Challenges - DirectorsTalk Interviews
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):